Page last updated: 2024-11-13

ly3000328

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LY3000328: a cathepsin S inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	67475270
CHEMBL ID	3342553
SCHEMBL ID	2618738
MeSH ID	M000610199

Synonyms (31)

Synonym
1373215-15-6
z-fl-cocho
NDEBZCZEAVMSQF-GOTSBHOMSA-N ,
[(3r,4s)-4-[(4-fluorobenzoyl)amino]-6-[4-(oxetan-3-yl)piperazin-1-yl]chroman-3-yl]n-methylcarbamate
ly 3000328
HY-15533
CS-1120
(3r,4s)-4-[(4-fluorobenzoyl)amino]-6-[4-(oxetan-3-yl)piperazin-1-yl]-3,4-dihydro-2h-chromen-3-yl methylcarbamate
2fz ,
SCHEMBL2618738
ly-3000328
n-((3r,4s)-3,4-dihydro-3-(((methylamino)carbonyl)oxy)-6-(4-(3-oxetanyl)-1-piperazinyl)-2h-1-benzopyran-4-yl)-4-fluorobenzamide
benzamide, n-((3r,4s)-3,4-dihydro-3-(((methylamino)carbonyl)oxy)-6-(4-(3-oxetanyl)-1-piperazinyl)-2h-1-benzopyran-4-yl)-4-fluoro-
1210T8CX6K ,
DTXSID40737323
(3r,4s)-4-(4-fluorobenzamido)-6-[4-(oxetan-3-yl)piperazin-1-yl]-3,4-dihydro-2h-1-benzopyran-3-yl methylcarbamate
bdbm50030823
CHEMBL3342553 ,
ly3000328
AKOS030526459
unii-1210t8cx6k
(3r,4s)-4-(4-fluorobenzamido)-6-[4-(oxetan-3-yl)piperazin-1-yl]-3,4-dihydro-2h-1-benzopyran-3-yl n-methylcarbamate
NCGC00378866-01
(3r,4s)-4-(4-fluorobenzamido)-6-(4-(oxetan-3-yl)piperazin-1-yl)chroman-3-yl methylcarbamate
EX-A2231
BS-15315
BCP14297
Q27452973
C72497
[(3r,4s)-4-[(4-fluorobenzoyl)amino]-6-[4-(oxetan-3-yl)piperazin-1-yl]-3,4-dihydro-2h-chromen-3-yl] n-methylcarbamate
cathepsin s inhibitorcathepsin s inhibitor

Research Excerpts

Treatment

Excerpt	Reference	Relevance
"Treatment with LY3000328, a selective inhibitor of Cat S, dose-dependently down-regulated EMG amplitude and Fractalkine (FKN) expression, indicating that Cat S regulated visceral hypersensitivity via activating FKN in IBS-like rats."	( Spinal Cathepsin S promotes visceral hypersensitivity via FKN/CX3CR1/p38 MAPK signaling pathways. Chen, A; Chen, Y; Gong, J; Huang, Y; Lin, C; Lin, W; Sun, P; Tang, Y; Weng, Y, )	0.47

Pharmacokinetics

Excerpt	Reference	Relevance
" The pharmacodynamic activity of LY3000328 was measured ex vivo showing a biphasic response to LY3000328, where CatS activity declines, then returns to baseline, and then increases to a level above baseline."	( Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects. Chan, M; DeBrota, DJ; Deeg, MA; LaBell, ES; Payne, CD; Shen, T; Tan, LH, 2014)	0.92

Bioavailability

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	37.9083	0.0123	7.9835	43.2770	AID1645841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cathepsin S	Mus musculus (house mouse)	IC50 (µMol)	0.0017	0.0003	2.4555	6.3500	AID1169037
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	0.0017	0.0000	2.0151	10.0000	AID1169037
Cathepsin S	Homo sapiens (human)	IC50 (µMol)	0.0077	0.0002	1.3191	10.0000	AID1169036
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (34)

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
toll-like receptor signaling pathway	Cathepsin S	Homo sapiens (human)
adaptive immune response	Cathepsin S	Homo sapiens (human)
proteolysis	Cathepsin S	Homo sapiens (human)
apoptotic process	Cathepsin S	Homo sapiens (human)
response to acidic pH	Cathepsin S	Homo sapiens (human)
protein processing	Cathepsin S	Homo sapiens (human)
antigen processing and presentation	Cathepsin S	Homo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class II	Cathepsin S	Homo sapiens (human)
extracellular matrix disassembly	Cathepsin S	Homo sapiens (human)
collagen catabolic process	Cathepsin S	Homo sapiens (human)
basement membrane disassembly	Cathepsin S	Homo sapiens (human)
antigen processing and presentation of peptide antigen	Cathepsin S	Homo sapiens (human)
proteolysis involved in protein catabolic process	Cathepsin S	Homo sapiens (human)
cellular response to thyroid hormone stimulus	Cathepsin S	Homo sapiens (human)
positive regulation of cation channel activity	Cathepsin S	Homo sapiens (human)
positive regulation of peptidase activity	Cathepsin S	Homo sapiens (human)
immune response	Cathepsin S	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Cathepsin S	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Process	via Protein(s)	Taxonomy
cysteine-type endopeptidase activity	Cathepsin S	Mus musculus (house mouse)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
fibronectin binding	Cathepsin S	Homo sapiens (human)
cysteine-type endopeptidase activity	Cathepsin S	Homo sapiens (human)
serine-type endopeptidase activity	Cathepsin S	Homo sapiens (human)
collagen binding	Cathepsin S	Homo sapiens (human)
laminin binding	Cathepsin S	Homo sapiens (human)
proteoglycan binding	Cathepsin S	Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic process	Cathepsin S	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Process	via Protein(s)	Taxonomy
early endosome lumen	Cathepsin S	Mus musculus (house mouse)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
extracellular region	Cathepsin S	Homo sapiens (human)
extracellular space	Cathepsin S	Homo sapiens (human)
lysosome	Cathepsin S	Homo sapiens (human)
late endosome	Cathepsin S	Homo sapiens (human)
endolysosome lumen	Cathepsin S	Homo sapiens (human)
lysosomal lumen	Cathepsin S	Homo sapiens (human)
intracellular membrane-bounded organelle	Cathepsin S	Homo sapiens (human)
phagocytic vesicle	Cathepsin S	Homo sapiens (human)
collagen-containing extracellular matrix	Cathepsin S	Homo sapiens (human)
tertiary granule lumen	Cathepsin S	Homo sapiens (human)
ficolin-1-rich granule lumen	Cathepsin S	Homo sapiens (human)
extracellular space	Cathepsin S	Homo sapiens (human)
lysosome	Cathepsin S	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (35)

Assay ID	Title	Year	Journal	Article
AID1169046	Volume of distribution in Beagle dog at 1 mg/kg, iv or 3 mg/kg, po	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169059	Inhibition of CaCl2-induced abdominal aortic aneurysm in 129SvEv mouse assessed as reduction in aortic diameter at 1 mg/kg dosed through oral gavage BID for 4 weeks with first dose given one day prior to surgery	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169053	Drug metabolism in human liver microsomes after 30 mins at 4 uM	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169037	Inhibition of mouse cathepsin S using benzyloxycarbonyl-L-Leucyl-L-Arginine 4-Methyl-coumaryl-7-amide substrate by FRET assay	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169055	Displacement of [3H]astemizole form human ERG expressed in HEK293 cell membranes at 100 uM	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169063	AUC (0 to 24 hrs) in 129SvEv mouse model of CaCl2-induced abdominal aortic aneurysm at 1 mg/kg dosed through oral gavage BID for 4 weeks with first dose given one day prior to surgery	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169051	Drug metabolism in rat liver microsomes after 30 mins at 4 uM	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169048	Inhibition of CYP2D6 (unknown origin) using bufuralol substrate at 10 uM	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169057	Stability in rat plasma assessed as loss of parent compound after 30 mins	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169045	Clearance in Beagle dog at 1 mg/kg, iv or 3 mg/kg, po	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169054	Permeability from apical to basolateral side in MDCK cells at 2.5 uM incubated for 1 hr	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169042	Dissociation constant, basic pKa of the compound	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169064	AUC (0 to 24 hrs) in 129SvEv mouse model of CaCl2-induced abdominal aortic aneurysm at 3 mg/kg dosed through oral gavage BID for 4 weeks with first dose given one day prior to surgery	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169036	Inhibition of human cathepsin S using benzyloxycarbonyl-L-Leucyl-L-Arginine 4-Methyl-coumaryl-7-amide substrate by FRET assay	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169049	Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169066	AUC (0 to 24 hrs) in 129SvEv mouse model of CaCl2-induced abdominal aortic aneurysm at 30 mg/kg dosed through oral gavage BID for 4 weeks with first dose given one day prior to surgery	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169041	Lipophilicity, log D of the compound at pH 4.0	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169040	Lipophilicity, log P of the compound	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169047	Inhibition of CYP3A4 (unknown origin) using midazolam substrate at 10 uM	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169044	Oral bioavailability in Beagle dog at 3 mg/kg	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169043	Solubility in simulated gastric fluid	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169058	Inhibition of CaCl2-induced abdominal aortic aneurysm in 129SvEv mouse assessed as reduction in aortic diameter at 1 to 30 mg/kg dosed through oral gavage BID for 4 weeks with first dose given one day prior to surgery	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169052	Drug metabolism in dog liver microsomes after 30 mins at 4 uM	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169065	AUC (0 to 24 hrs) in 129SvEv mouse model of CaCl2-induced abdominal aortic aneurysm at 10 mg/kg dosed through oral gavage BID for 4 weeks with first dose given one day prior to surgery	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169056	Stability in human plasma assessed as loss of parent compound after 30 mins	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169060	Inhibition of CaCl2-induced abdominal aortic aneurysm in 129SvEv mouse assessed as reduction in aortic diameter at 3 mg/kg dosed through oral gavage BID for 4 weeks with first dose given one day prior to surgery	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169050	Drug metabolism in mouse liver microsomes after 30 mins at 4 uM	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169062	Inhibition of CaCl2-induced abdominal aortic aneurysm in 129SvEv mouse assessed as reduction in aortic diameter at 30 mg/kg dosed through oral gavage BID for 4 weeks with first dose given one day prior to surgery	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169061	Inhibition of CaCl2-induced abdominal aortic aneurysm in 129SvEv mouse assessed as reduction in aortic diameter at 10 mg/kg dosed through oral gavage BID for 4 weeks with first dose given one day prior to surgery	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1169038	Inhibition of rat cathepsin S G137C mutant using benzyloxycarbonyl-L-Leucyl-L-Arginine 4-Methyl-coumaryl-7-amide substrate by FRET assay	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (57.14)	24.3611
2020's	3 (42.86)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	19.89 (24.57)
Research Supply Index	2.30 (2.92)
Research Growth Index	4.56 (4.65)
Search Engine Demand Index	15.26 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (19.89)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (12.50%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (87.50%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
carbamates [no description available]	4.23	3	1	amino-acid anion

Condition	Relationship Strength	Studies
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.69	2
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Innate Inflammatory Response [description not available]	2.31	1
Cardiovascular Stroke [description not available]	2.31	1
Injury, Ischemia-Reperfusion [description not available]	2.31	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.31	1
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	2.31	1
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	2.31	1
Bacteroides Infections Infections with bacteria of the genus BACTEROIDES.	2.13	1
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	2.13	1

chemdatabank.com